Skip to main content
. 2015 Aug 26;67(9):2487–2494. doi: 10.1002/art.39197

Table 5.

HRs for infection in patients taking ETN versus MTX, by time intervala

No. of first infections No. of patients at risk Fully adjusted HR (95% CI)
MTX Taking ETN MTX Taking ETN MTX Taking ETN
MSIs
Time points
0–6 months 9 48 260 852 Reference 2.00 (0.89–4.46)
6–12 months 6 26 211 716 Reference 1.09 (0.43–2.78)
12–18 months 4 18 160 564 Reference 2.68 (0.58–12.42)
18–24 months 1 16 138 470 Reference 4.13 (0.51–33.50)
SIs
Time points
0–6 months 5 24 260 852 Reference 0.93 (0.32–2.73)
6–12 months 5 12 215 738 Reference 0.36 (0.11–1.231)
12–18 months 2 9 166 595 Reference 1.61 (0.19–13.86)
18–24 months 1 9 143 506 Reference 1.37 (0.15–12.19)
a

Hazard ratios (HRs) were fully adjusted using propensity deciles (including age, sex, Childhood Health Assessment Questionnaire score, Juvenile Arthritis Disease Activity Score in 71 joints, concurrent steroid use, and International League of Associations for Rheumatology category). ETN = etanercept; MTX = methotrexate; 95% CI = 95% confidence interval.